Abstract
The bcl-2 gene encodes for a mitochondrial membrane proto-oncoprotein, the expression of which is known to suppress programmed cell death (apoptosis). In the present study the prognostic value of bcl-2 proto-oncoprotein was immunohistochemically investigated in a series of 104 colorectal carcinomas. The bcl-2 staining patterns were semiquantitatively assessed and correlated with the pTNM stage, Dukes' classification, lymphocytic infiltration (Jass classification) and tumour grade as well as parameters not associated with prognosis (gender, age, tumour site, histological tumour type). Statistical analysis was carried out using the Kaplan-Meier method, the log-rank test, hazard ratios and their confidence intervals. Fifty-five out of 104 cases completely lacked immunohistochemical bcl-2 expression. Fewer than 5% of bcl-2-positive cells were found in 25, 5-50% in 17 and more than 50% in five cases. The extent of bcl-2 expression by tumour cells decreased significantly with respect to increasing tumour size (P < 0.05), decreasing lymphocytic infiltration (P < 0.05) and chance of poor clinical outcome (P < 0.05), but not with worsening of Dukes stages. In multivariate analysis (Cox regression model) bcl-2 expression remained as an independent prognostic parameter with Dukes' classification as stratification factor (P < 0.001). Although the biological functions of bcl-2 protein are not yet well understood, our results provide further evidence that bcl-2 oncoprotein appears to be associated with favourable clinical outcome. Thus immunohistochemical bcl-2 phenotyping of colorectal carcinoma may contribute in future to the clinical management of these patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Öfner, D., Riehemann, K., Maier, H. et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 72, 981–985 (1995). https://doi.org/10.1038/bjc.1995.446
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.446
This article is cited by
-
Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer
Tumor Biology (2016)
-
How cell death shapes cancer
Cell Death & Disease (2015)
-
Genetic unraveling of colorectal cancer
Tumor Biology (2014)
-
Gender-Related Differences in Pathological and Clinical Tumor Response Based on Immunohistochemical Proteins Expression in Rectal Cancer Patients Treated with Short Course of Preoperative Radiotherapy
Journal of Gastrointestinal Surgery (2014)
-
The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia
BMC Cancer (2013)